These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 3621212)
1. Antineoplastic agents and FDA regulations: square pegs for round holes? Wittes RE Cancer Treat Rep; 1987 Sep; 71(9):795-806. PubMed ID: 3621212 [No Abstract] [Full Text] [Related]
2. Subjective response criteria and quality of life. Aaronson NK; Calais da Silva F; de Voogt HJ Prog Clin Biol Res; 1988; 269():261-73. PubMed ID: 3293064 [No Abstract] [Full Text] [Related]
3. Adaptive design may hasten clinical trials. Schmidt C J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993 [No Abstract] [Full Text] [Related]
4. Pharmaceutics: clinical trials--a review of terms and principles: part I. Reich SD Cancer Nurs; 1982 Jun; 5(3):232-3. PubMed ID: 6919461 [No Abstract] [Full Text] [Related]
5. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Gondek K; Sagnier PP; Gilchrist K; Woolley JM J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926 [TBL] [Abstract][Full Text] [Related]
6. [Measurement of health-related quality of life in malignant diseases. Does it have any consequences?]. Wisløff F Tidsskr Nor Laegeforen; 1997 Oct; 117(26):3812-6. PubMed ID: 9417687 [TBL] [Abstract][Full Text] [Related]
7. [Current problems in the experimental therapy of malignant neoplasms]. Aleksandrov SN Vopr Onkol; 1974; 20(5):5-10. PubMed ID: 4612984 [No Abstract] [Full Text] [Related]
8. Controlled prophylactic trials in cancer. Magnus K; Miller AB J Natl Cancer Inst; 1980 Apr; 64(4):693-9. PubMed ID: 6928983 [No Abstract] [Full Text] [Related]
9. Can a rational design for metronomic chemotherapy dosing be devised? Maraveyas A; Lam T; Hetherington JW; Greenman J Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302 [No Abstract] [Full Text] [Related]
12. Clinical development of anticancer agents--a National Cancer Institute perspective. Marsoni S; Wittes R Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870 [No Abstract] [Full Text] [Related]
13. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
14. Enrichment designs: efficiency in development of cancer treatments. Temple RJ J Clin Oncol; 2005 Aug; 23(22):4838-9. PubMed ID: 15983397 [No Abstract] [Full Text] [Related]
15. Cancer clinical trials: development and implementation. Vail DM Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881 [TBL] [Abstract][Full Text] [Related]
16. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Arteaga CL; Baselga J Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709 [No Abstract] [Full Text] [Related]
17. Improving the evaluation of new cancer treatments: challenges and opportunities. Rothenberg ML; Carbone DP; Johnson DH Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669 [TBL] [Abstract][Full Text] [Related]
18. Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics. Eisenberg PD Semin Oncol; 1994 Jun; 21(3 Suppl 5):26-9. PubMed ID: 8042034 [No Abstract] [Full Text] [Related]
19. Surrogate outcomes in quality-of-life research: where will we end up? Tassinari D; Panzini I; Sartori S; Ravaioli A J Clin Oncol; 2003 May; 21(9):1894-5; author reply 1895. PubMed ID: 12721275 [No Abstract] [Full Text] [Related]
20. Phase II trials in journal of clinical oncology. Cannistra SA J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415 [No Abstract] [Full Text] [Related] [Next] [New Search]